Heparin-Induced Thrombocytopenia

Hematology/Oncology Clinics of North America

Volumn 21, Issue 4, 2007, Pages 589-607

  Warkentin, Theodore E ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

^c HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA CHEMOKINE; ARGATROBAN; COUMARIN; DANAPAROID; DEXTRAN 70; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROCOAGULANT; QUININE; THROMBIN; THROMBOCYTE FACTOR 4; VANCOMYCIN; WARFARIN;

ARTERY THROMBOSIS; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ACCUMULATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENZYME IMMUNOASSAY; GANGRENE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LABORATORY TEST; LIMB ISCHEMIA; MICROTHROMBUS; NEUTROPHIL; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SEX DIFFERENCE; SKIN NECROSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; VEIN THROMBOSIS; VENOUS LIMB GANGRENE;

ANTIBODIES; ANTICOAGULANTS; HEPARIN; HUMANS; PLATELET ACTIVATION; PLATELET FACTOR 4; THROMBOCYTOPENIA;

EID: 34547099318     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.06.004     Document Type: Review

References (50)

1. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121 4 (2003) 535-555
2. Arepally G.M., and Ortel T.L. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355 8 (2006) 809-817
3. Warkentin T.E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 110 2-3 (2003) 73-82
4. Warkentin T.E., Elavathil L.J., Hayward C.P.M., et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 127 9 (1997) 804-812
5. Warkentin T.E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-induced thrombocytopenia. 4th edition (2007), Informa Healthcare USA, Inc., New York 21-66
6. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 20 (1995) 1330-1335
7. Warkentin T.E., Roberts R.S., Hirsh J., et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 163 20 (2003) 2518-2524
8. Greinacher A., Farner B., Kroll H., et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 94 1 (2005) 132-135
9. Warkentin T.E., and Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101 5 (1996) 502-507
10. Warkentin T.E. Pseudo-heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-induced thrombocytopenia. 4th edition (2007), Informa Healthcare USA, Inc., New York 261-282
11. Warkentin T.E. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann Intern Med 135 8 Pt 1 (2001) 589-593
12. Warkentin T.E. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 30 3 (2004) 273-283
13. Kelton J.G., Sheridan D., Santos A., et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 72 3 (1988) 925-930
14. Warkentin T.E., Sheppard J.I., Moore J.C., et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 146 6 (2005) 341-346
15. Greinacher A., Pötzsch B., Amiral J., et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 71 2 (1994) 247-251
16. Suh J.S., Aster R.H., and Visentin G.P. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin:platelet factor 4. Blood 91 3 (1998) 916-922
17. Greinacher A., Gopinadhan M., Guenther J.U., et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 26 10 (2006) 2386-2393
18. Warkentin T.E., Sheppard J.I., Siguoin C.S., et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 108 9 (2006) 2937-2941
19. Warkentin T.E., Cook R.J., Marder V.J., et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106 12 (2005) 3791-3796
20. Warkentin TE, Eikelboom JW. Who is (still) getting HIT? Chest 2007;131:1620-2.
21. Lee D.H., and Warkentin T.E. Frequency of heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-Induced Thrombocytopenia. 4th edition (2007), Informa Healthcare USA, Inc., New York 67-116
22. Fausett M.B., Vogtlander M., Lee R.M., et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 185 1 (2001) 148-152
23. Warkentin T.E. Drug-induced immune-mediated thrombocytopenia: from purpura to thrombosis. N Engl J Med 356 9 (2007) 891-893
24. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 17 (2001) 1286-1292
25. Warkentin T.E., and Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135 7 (2001) 502-506
26. Rauova L., Zhai L., Kowalska M.A., et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 107 6 (2006) 2346-2353
27. Warkentin T.E., Jay R.M., Makris M., et al. Platelet-activating anti-platelet factor 4/polyanion antibodies without preceding heparin therapy: a transient autoimmune disorder resembling heparin-induced thrombocytopenia ("spontaneous HIT"). [abstract]. Blood 108 11 (2006) 311a-312a
28. Warkentin T.E. Think of HIT. Hematology Am Soc Hematol Educ Program (2006) 408-414
29. Greinacher A., Eichler P., Lietz T., et al. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 106 8 (2005) 2921-2922
30. Warkentin T.E. Think of HIT when thrombosis follows heparin. Chest 130 3 (2006) 631-632
31. Warkentin T.E. Heparin-induced skin lesions. Br J Haematol 92 2 (1996) 494-497
32. Warkentin T.E., Hirte H.W., Anderson D.R., et al. Transient global amnesia following intravenous heparin bolus therapy is caused by heparin-induced thrombocytopenia. Thromb Haemost 97 5 (1994) 489-491
33. Lo G.K., Juhl D., Warkentin T.E., et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4 4 (2006) 759-765
34. Warkentin T.E., and Sheppard J.I. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 20 4 (2006) 259-272
35. Warkentin T.E. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 127 Suppl 2 (2005) 35S-45S
36. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol, in press.
37. Warkentin T.E., Hayward C.P.M., Smith C.A., et al. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 120 3 (1992) 371-379
38. Greinacher A., Michels I., Kiefel V., et al. A rapid and sensitive test for diagnosing heparin-induced thrombocytopenia. Thromb Haemost 66 6 (1991) 734-736
39. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; May 7 [epub ahead of print].
40. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 Suppl 3 (2004) 311S-337S
41. Warkentin T.E. Heparin-induced thrombocytopenia: diagnosis and management. Circulation 110 18 (2004) e454-e458
42. Chong B.H., Gallus A.S., Cade J.F., et al. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. Thromb Haemost 86 5 (2001) 1170-1175
43. Lubenow N., Eichler P., Lietz T., et al. Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3 11 (2005) 2428-2436
44. Greinacher A., Eichler P., Lubenow N., et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96 3 (2000) 846-851
45. Lewis B.E., Wallis D.E., Berkowitz S.D., et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103 14 (2001) 1838-1843
46. Lewis B.E., Wallis D.E., Leya F., et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163 15 (2003) 1849-1856
47. Lewis B.E., Wallis D.E., Hursting M.J., et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 129 6 (2006) 1407-1416
48. Lubenow N., Eichler P., Lietz T., et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 104 10 (2004) 3072-3077
49. Greinacher A., and Warkentin T.E. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-induced thrombocytopenia. 4th edition (2007), Informa Healthcare USA, Inc., New York 283-317
50. Warkentin T.E. Should vitamin K be administered when HIT is diagnosed after administration of coumarin?. J Thromb Haemost 4 (2006) 894-896